US Consumer Health Sector Seizing Opportunity To Market Products, Services To GLP-1 Patients

Latest moves on selling to consumers using GLP-1 receptor agonist drugs for obesity come from firms as large as global food products manufacturer and marketer Nestle and as small as startup Promino and as ambitious as men’s health product marketer Ro offering an app at no charge to find GLP-1 drugs.

• Source: Shutterstock

The latest signs of the consumer health product sector’s interest in driving sales through marketing to consumers using GLP-1 drugs for weight loss suggest the size of the opportunity.

That’s because the latest plays related to selling to consumers using glucagon-like peptide-1 receptor agonist drugs indicated for type 2 diabetes and obesity come from firms as large as a global food products manufacturer and marketer and as small as a startup restarting its business and as ambitious

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Digital Technologies

Value Of Consumer Wearables Within The Clinic Currently Unknown, Says Cardiologist

 

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”

Bayer Study Shows Potential Of Saliva-Based Biomarker For Healthy Aging

 
• By 

Bayer Consumer Health hopes its new InflammAge saliva-based biomarker can help “revolutionize self-care and how people can manage their aging journey.”

Church & Dwight Launching Sugar-Free Vitafusion, Looks To AI As Sweet Spot For All Growth

 

AI prowess “will not be a competitive advantage long-term. It's going to be table stakes. But there are people who are going to get there sooner and they will have an advantage for a while,” says C&D CEO Matthew Farrell. P&G’s investment in AI, meanwhile, produced its “Great Idea Generator proprietary platform.”

EU Industry Calls For Earlier And Harmonized Adoption Of Electronic Product Information

 
• By 

Electronic product information should be “fully operational” within four years after the entry into force of the revised EU pharma legislation and should precede the phasing out of paper leaflets, proposes the Inter-Association Taskforce (IATF) on ePI. Once the new system is up and running, ePI should be implemented across the EU in a harmonized way, with all EU member states adopting the same standard, it says.

More from HBW Insight

J&J Plots Next Steps Following Third Failure To Resolve Talc Cases Through Bankruptcy

 
• By 

After a Texas judge denied a bankruptcy plan, Johnson & Johnson attorneys plan to focus on debunking what they see as dubious scientific claims in civil court.

US FDA Supplement Office Chief Eyes ‘Movement’ This Year On NDI Notifications Final Guidance

 

“We've made some progress and really hope to see some movement as we move forward this year,” says FDA Office of Dietary Supplement Programs director Cara Welch.

People On The Move: Appointments At ANEPF, Inula, Opella

 
• By 

A round-up of the latest consumer health people moves: ANEFP elects president; Inula Group appoints CEO; Opella names ANZ head.